Sanofi makes $15.4M gender bias deal with reps

Sanofi-Aventis sales reps have won a settlement in their gender bias case against the company, but it's a small fraction of the big Novartis deal announced last week. One-tenth of the size, to be exact. Lawyers for the 5,200 current and former Sanofi reps asked a judge to approve a $15.36 million settlement; Novartis agreed to pay $152.5 million to 5,600 female reps.

Like Novartis, Sanofi will be required to overhaul internal policies of pay and promotions for female sales folks. The French drugmaker must beef up its compliance procedures, too. The deal will get a hearing August 3 in Manhattan federal court.

The settlement requires Sanofi to increase females' salaries if gender disparities in pay are found, Reuters reports. Some $13.4 million on top of that $15.36 million will go to adjust employees' pay; after attorney's fees of $4.5 million, the Sanofi women will get a total of more than $24 million. In the Novartis settlement, the company agreed to an improvement program costing $22.5 million, bringing total relief to some $175 million.

- see the proposed settlement
- get the news from Reuters

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.